Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
Interventions: rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC); Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years to 81 Years
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Fleming Island, Florida + 25 more

Conditions: Diabetes
Interventions: Saxagliptin, Metformin, Placebo, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Concord, California • Encinitas, California • Orange, California + 38 more

Conditions: Acne Vulgaris
Interventions: Tazarotene Cream 0.1%, Tazorac®, Placebo; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more

Conditions: Stress, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Mindfulness Based Stress Reduction, Stress Management Education; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Autoimmune Diseases, Multiple Sclerosis
Interventions: LPX-TI641; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dilworth, Minnesota

Conditions: Depression
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Mood
Interventions: Botulinum Neurotoxin, Placebo; Drug
Lead sponsor: DeNova Research; Other
Eligibility: 10 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fibrostenotic Crohn's Disease
Interventions: Ontunisertib, Placebo; Drug
Lead sponsor: Agomab Spain S.L.U.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Sun City, Arizona • Bradenton, Florida • Albany, New York + 4 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine, FLU HD vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 1,029 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 46
States / cities: Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more

Conditions: Abuse Potential
Interventions: Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
Interventions: placebo, tanezumab; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 56
States / cities: Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more

Conditions: Healthy
Interventions: FosD, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: BMS-986196, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Ischemic Heart Disease
Interventions: GS-6615, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hot Flashes, Prostate Cancer
Interventions: gabapentin, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 170
States / cities: Mobile, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 103 more

Conditions: Migraine
Interventions: DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C); Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more

Conditions: Anxiety, Autism Spectrum Disorder
Interventions: Bergamot Aromatherapy; Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 6 Years to 11 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Alzheimer's Disease
Interventions: memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 9
States / cities: San Francisco, California • Westminster, California • New Haven, Connecticut + 6 more

Conditions: Influenza A Virus, H1N1 Subtype
Interventions: Zanamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: nikkomycin Z; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Asthma
Interventions: Montelukast 5-mg orally added to standard therapy; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 14 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Back Pain, Neck Pain, Sleep Initiation and Maintenance Disorders
Interventions: Magnetic Sleep Pad; Device
Lead sponsor: Weintraub, Michael I., MD, FACP, FAAN; Individual
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Briarcliff Manor, New York

Conditions: Healthy
Interventions: Entolimod, Placebo, Influenza vaccine; Drug
Lead sponsor: Robert J. Pignolo; Other
Eligibility: 65 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Decreasing Stress in Diabetes

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

EEG Synchronized TMS Trial for Depression

Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction

NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

Aromatherapy for Anxiety Among Children With Autism Spectrum Disorder

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

Safety and PK of Nikkomycin Z in Healthy Subjects

Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years

Study on Magnetic Field Therapy to Improve Quality of Sleep and Reduction of Chronic Spine Pain

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination